Following meetings with then-Commissioner Scott Gottlieb and senior leadership from the Center for Drug Evaluation and Research on the role of CROs and technology companies in designing and implementing risk-based monitoring (RBM) of clinical trials, the Association...
Phase I clinical trial to evaluate safety and tolerability of ATR-002 in healthy volunteers ATR-002 expected to show high resilience to viral resistance and prolonged treatment window Novel approach to treating influenza, one of the most prominent global health...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the dosing of the first patient in its Phase 1 clinical trial of DCR-HBVS, the...
-Company strengthens board of directors and scientific advisory board with appointments of Mike Raab and Benjamin Cravatt– Tempest Therapeutics Inc., a clinical-stage biotechnology company developing a broad portfolio of first-in-class immunomodulatory small...
FDA Lifts Clinical Hold on Second Cohort to Allow Dose Escalation Robust Preliminary Anatomical Response from First Cohort Leads Adverum to Begin Dosing Second Cohort at Lower Dose MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc....
Viracta Therapeutics, Inc. announced today that it will present new clinical data during a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31 to June 4, 2019 in Chicago, IL. Viracta researchers and study...
Email
Text